Akkermansia muciniphila alleviates high‐fat‐diet ‐related metabolic‐associated fatty liver disease by modulating gut microbiota and bile acids
Microbial Biotechnology · 2023-10 · 16 (10) · 1924-1939
DOI: 10.1111/1751-7915.14293 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Biotechnology, online erschienen am 28.06.2023. Verfasst von Wenrui Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical …. Hauptthemen laut MEDLINE: Liver Diseases, Gastrointestinal Microbiome, Metabolic Diseases. Die Arbeit wurde bisher 137-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Basic Research Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
It has been reported that Akkermansia muciniphila improves host metabolism and reduces inflammation; however, its potential effects on bile acid metabolism and metabolic patterns in metabolic‐associated fatty liver disease (MAFLD) are unknown. In this study, we have analysed C57BL/6 mice under three feeding conditions: (i) a low‐fat diet group (LP), (ii) a high‐fat diet group (HP) and (iii) a high‐fat diet group supplemented with A. muciniphila (HA). The results found that A. muciniphila administration relieved weight gain, hepatic steatosis and liver injury induced by the high‐fat diet. A. muciniphila altered the gut microbiota with a decrease in Alistipes , Lactobacilli , Tyzzerella , Butyricimonas and Blautia , and an enrichment of Ruminiclostridium , Osclibacter , Allobaculum , Anaeroplasma and Rikenella . The gut microbiota changes correlated significantly with bile acids. Meanwhile, A. muciniphila also improved glucose tolerance, gut barriers and adipokines dysbiosis. Akkermansia muciniphila regulated the intestinal FXR‐FGF15 axis and reshaped the construction of bile acids, with reduced secondary bile acids in the caecum and liver, including DCA and LCA. These findings provide new insights into the relationships between probiotics, microflora and metabolic disorders, highlighting the potential role of A. muciniphila in the management of MAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Di…
- Jinan Microecological Biomedicine Shandong Laboratory, Jinan, Shandong, China.
ORCID-Profile: Lanjuan Li
Förderung
- National Basic Research Program of China
- National Natural Science Foundation of China
Zitieren
APA
Wu, W., Kaicen, W., Bian, X., Yang, L., Ding, S., Li, Y., Li, S., Zhuge, A., & Li, L. (2023). Akkermansia muciniphila alleviates high‐fat‐diet ‐related metabolic‐associated fatty liver disease by modulating gut microbiota and bile acids. Microbial Biotechnology, 16(10), 1924-1939. https://doi.org/10.1111/1751-7915.14293
Vancouver
Wu W, Kaicen W, Bian X, Yang L, Ding S, Li Y, et al. Akkermansia muciniphila alleviates high‐fat‐diet ‐related metabolic‐associated fatty liver disease by modulating gut microbiota and bile acids. Microbial Biotechnology. 2023;16(10):1924-1939. doi:10.1111/1751-7915.14293
BibTeX
@article{Wu2023,
author = {Wu, Wenrui and Kaicen, Wang and Bian, Xiaoyuan and Yang, Liya and Ding, Shi and Li, Yating and Li, Shengjie and Zhuge, Aoxiang and Li, Lanjuan},
title = {Akkermansia muciniphila alleviates high‐fat‐diet ‐related metabolic‐associated fatty liver disease by modulating gut microbiota and bile acids},
journal = {Microbial Biotechnology},
year = {2023},
volume = {16},
number = {10},
pages = {1924--1939},
doi = {10.1111/1751-7915.14293}
}
EUVIMED